Dr. Wang on the Safety Profile of KTE-X19 in MCL

Video

Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, according to results from the phase II ZUMA-2 trial.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma (MCL), according to results from the phase II ZUMA-2 trial.

At a median follow-up of 12.3 months, results from the ZUMA-2 trial showed an overall response rate of 93% with a complete response rate of 67%. These results led to the FDA granting KTE-X19 priority review in patients with relapsed/refractory MCL.

KTE-X19 also had a tolerable safety profile, according to Wang. Out of 68 patients, 15% experienced grade 3 cytokine release syndrome (CRS) and 30% experienced neurotoxicity. No patients died from CRS or neurotoxicity and the majority of CRS and neurotoxicity is reversible. Meanwhile, 2 patients died from infections due to the CAR T-cell therapy, concludes Wang.

Related Videos
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Luke Roberts, MBBS, PhD, on Early Clinical Data on Congestive Heart Failure Gene Therapy
Lawrence R. Lustig, MD, the chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians
Casey Maguire, PhD, on Combining Viral-Like Particles and AAV
Travis Drow, BS, a research scientist at Seattle Children's Research Institute
Holly Peay, PhD, senior research scientist at RTI International
Carlos Ramos, MD, on Alternatives to T-Cell Therapy
Omer A. Abdul Hamid, MD, on Sharing Expertise With Gene Therapy Logistics
Holly Peay, PhD, senior research scientist at RTI International
Terence R. Flotte, MD, the vice president of ASGCT and the provost and executive deputy chancellor of UMass Chan Medical School
Related Content
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital

Evaluating Autologous Cord Blood Derived Cells for the Treatment of Preterm Infants

April 8th 2024
Article

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital, discussed his lab’s research in the field of neonatal cell therapy.

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital

Standardized Guidelines for Preclinical Testing and Cell Characterization are Critical to Cell Therapy Development

April 3rd 2024
Article

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital, discussed the importance of preclinical guidelines in the context of neonatal cell therapy.

David Taylor, PhD

New Findings May Help Bolster CRISPR/Cas9 Accuracy

March 4th 2022
Article

David Taylor, PhD, an assistant professor in the department of molecular biosciences at UT Austin, discussed the Cas9 research conducted between 2 labs at UT Austin.

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

June 27th 2021
Article

The recommendation comes after positive data was released from the recent phase 2 KarMMa trial.

Mariana Nacht, PhD

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

June 9th 2021
Article

The therapy utilizes LogicBio’s GeneRide technology to insert a corrective copy of the target gene via synthetic AAV vectors.

© 2024 MJH Life Sciences

All rights reserved.